

EXHIBIT 2



Elevor Therapeutics

Elevor Therapeutics is a rapidly growing, fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options. Our experience is rooted in oncology, and we apply the same rigor and diligence that comes with this knowledge to identifying and developing promising medicines for complex yet under-treated health conditions across a range of therapeutic areas.

Evolving Therapeutic Potential



Elevor Latest News

Elevar Therapeutics Announces Promotion of Mark Gelder, M.D. to Chief Medical Officer

January 12, 2021

Elevar Therapeutics Appoints Gus Aromin as Vice President of Regulatory Affairs

November 30, 2020

Elevar Therapeutics Announces Early Completion of Initial Target Enrollment in Pivotal Phase 2 Study Evaluating Rivoceranib (apatinib) in Adenoid Cystic Cancer (ACC)

November 17, 2020

Elevar Therapeutics Announces Licensing Agreement with Inceptua Group for Commercialization of Apealea® (Paclitaxel Micellar) in Europe

December 27, 2020

Elevar Therapeutics Presents Safety and Efficacy Results of Rivoceranib (apatinib) in Combination with Nivolumab at the 2020 Connective Tissue Oncology Society (CTOS) Annual Meeting

November 19, 2020

Elevar Therapeutics and Taiba Middle East FZ LLC Partner to Commercialize Apealea® (paclitaxel micellar) in the Middle East and North Africa Region

October 5, 2020

South San
Francisco U.S.

400 Oyster Point
Blvd, Suite 214
South San Francisco,
CA 94080
U.S.A.

Salt Lake City
U.S.
[Headquarters]

2825 E Cottonwood
Pkwy Suite 180,
Salt Lake City, UT
84121
U.S.A.

Phone: 801-303-7440
Fax: 801-303-7455

South Korea

7F Mayple Tower,
Teheran-ro 420,
Gangnam-gu, Seoul
06193
Republic of Korea

Ireland

The Black Church,
St Mary's Place,
Dublin, D07 P4AX,
Ireland

Phone: 353-1-969-
6739
Fax: 353-1-685-3040

